Raras
Buscar doenças, sintomas, genes...
Neuropatia óptica autossômica dominante
ORPHA:98672DOENÇA RARA

Uma doença genética hereditária de padrão dominante, caracterizada por atrofia do nervo óptico e perda progressiva da visão.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Uma doença genética hereditária de padrão dominante, caracterizada por atrofia do nervo óptico e perda progressiva da visão.

Pesquisas ativas
4 ensaios
9 total registrados no ClinicalTrials.gov
Publicações científicas
346 artigos
Último publicado: 2026 Apr 21

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-9 / 100 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
10.0
Denmark
Início
Childhood
🏥
SUS: Sem cobertura SUSScore: 0%
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

👁️
Olhos
28 sintomas
🧠
Neurológico
28 sintomas
💪
Músculos
13 sintomas
❤️
Coração
4 sintomas
📏
Crescimento
4 sintomas
🦴
Ossos e articulações
4 sintomas

+ 41 sintomas em outras categorias

Características mais comuns

Consciência/confusão reduzida
Anormalidade dos potenciais visuais evocados
Ptose bilateral
EMG: sinais de desnervação crônica
Miopatia mitocondrial
Fraqueza muscular da cintura escapular/pélvica
129sintomas
Sem dados (129)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 129 características clínicas mais associadas, ordenadas por frequência.

Consciência/confusão reduzidaReduced consciousness/confusion
Anormalidade dos potenciais visuais evocadosAbnormality of visual evoked potentials
Ptose bilateralBilateral ptosis
EMG: sinais de desnervação crônicaEMG: chronic denervation signs
Miopatia mitocondrialMitochondrial myopathy

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico346PubMed
Últimos 10 anos158publicações
Pico202521 papers
Linha do tempo
2026Hoje · 2026🧪 2008Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

4 genes identificados com associação a esta condição. Padrão de herança: Autosomal dominant.

DNM1LDynamin-1-like proteinDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Functions in mitochondrial and peroxisomal division (PubMed:11514614, PubMed:12499366, PubMed:17301055, PubMed:17460227, PubMed:17553808, PubMed:18695047, PubMed:18838687, PubMed:19342591, PubMed:19411255, PubMed:19638400, PubMed:23283981, PubMed:23530241, PubMed:23921378, PubMed:26992161, PubMed:27145208, PubMed:27145933, PubMed:27301544, PubMed:27328748, PubMed:29478834, PubMed:32439975, PubMed:32484300, PubMed:9570752, PubMed:9786947). Mediates membrane fission through oligomerization into me

LOCALIZAÇÃO

Cytoplasm, cytosolGolgi apparatusEndomembrane systemMitochondrion outer membranePeroxisomeMembrane, clathrin-coated pitCytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane

VIAS BIOLÓGICAS (1)
Apoptotic execution phase
EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
97.7 TPM
Cerebelo
77.7 TPM
Brain Frontal Cortex BA9
61.7 TPM
Linfócitos
57.7 TPM
Fibroblastos
52.2 TPM
OUTRAS DOENÇAS (3)
optic atrophy 5encephalopathy, lethal, due to defective mitochondrial peroxisomal fission 1autosomal dominant optic atrophy, classic form
HGNC:2973UniProt:O00429
ATP1A3Sodium/potassium-transporting ATPase subunit alpha-3Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates the electrochemical gradient of sodium and potassium ions, providing the energy for active transport of various nutrients

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (3)
Ion homeostasisIon transport by P-type ATPasesPotential therapeutics for SARS
MECANISMO DE DOENÇA

Dystonia 12

An autosomal dominant dystonia-parkinsonism disorder. Dystonia is defined by the presence of sustained involuntary muscle contractions, often leading to abnormal postures. DYT12 patients develop dystonia and parkinsonism between 15 and 45 years of age. The disease is characterized by an unusually rapid evolution of signs and symptoms. The sudden onset of symptoms over hours to a few weeks, often associated with physical or emotional stress, suggests a trigger initiating a nervous system insult resulting in permanent neurologic disability.

OUTRAS DOENÇAS (6)
developmental and epileptic encephalopathy 99cerebellar ataxia-areflexia-pes cavus-optic atrophy-sensorineural hearing loss syndromedystonia 12alternating hemiplegia of childhood 2
HGNC:801UniProt:P13637
OPA3Optic atrophy 3 proteinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

May play some role in mitochondrial processes

LOCALIZAÇÃO

Mitochondrion

MECANISMO DE DOENÇA

3-methylglutaconic aciduria 3

An autosomal recessive metabolic disorder that causes a neuro-ophthalmologic syndrome consisting of early-onset bilateral optic atrophy, spasticity, extrapyramidal dysfunction and cognitive deficit. Urinary excretion of 3-methylglutaconic acid and 3-methylglutaric acid is increased. MGCA3 can be distinguished from MGCA1 by the absence of increase of 3-hydroxyisovaleric acid levels.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
11.2 TPM
Pituitária
8.7 TPM
Fibroblastos
7.7 TPM
Glândula adrenal
7.7 TPM
Baço
7.2 TPM
OUTRAS DOENÇAS (2)
optic atrophy 33-methylglutaconic aciduria type 3
HGNC:8142UniProt:Q9H6K4
OPA1Dynamin-like GTPase OPA1, mitochondrialDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Dynamin-related GTPase that is essential for normal mitochondrial morphology by mediating fusion of the mitochondrial inner membranes, regulating cristae morphology and maintaining respiratory chain function (PubMed:16778770, PubMed:17709429, PubMed:20185555, PubMed:24616225, PubMed:28628083, PubMed:28746876, PubMed:31922487, PubMed:32228866, PubMed:32567732, PubMed:33130824, PubMed:33237841, PubMed:37612504, PubMed:37612506). Exists in two forms: the transmembrane, long form (Dynamin-like GTPas

LOCALIZAÇÃO

Mitochondrion inner membraneMitochondrion intermembrane space

VIAS BIOLÓGICAS (2)
Regulation of ApoptosisMitochondrial protein degradation
MECANISMO DE DOENÇA

Optic atrophy 1

A condition that features progressive visual loss in association with optic atrophy. Atrophy of the optic disk indicates a deficiency in the number of nerve fibers which arise in the retina and converge to form the optic disk, optic nerve, optic chiasm and optic tracts. OPA1 is characterized by an insidious onset of visual impairment in early childhood with moderate to severe loss of visual acuity, temporal optic disk pallor, color vision deficits, and centrocecal scotoma of variable density.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
41.7 TPM
Fibroblastos
33.7 TPM
Cérebro - Hemisfério cerebelar
29.1 TPM
Brain Frontal Cortex BA9
28.8 TPM
Artéria tibial
26.8 TPM
OUTRAS DOENÇAS (6)
optic atrophy with or without deafness, ophthalmoplegia, myopathy, ataxia, and neuropathyautosomal dominant optic atrophy, classic formBehr syndromemitochondrial DNA depletion syndrome 14 (cardioencephalomyopathic type)
HGNC:8140UniProt:O60313

Medicamentos aprovados (FDA)

1 medicamento encontrado nos registros da FDA americana.

💊 Jynarque (TOLVAPTAN)
Ver no DailyMed/FDA

Variantes genéticas (ClinVar)

640 variantes patogênicas registradas no ClinVar.

🧬 DNM1L: NM_012062.5(DNM1L):c.1979_1982del (p.Lys660fs) ()
🧬 DNM1L: GRCh38/hg38 12p11.21-11.1(chr12:32600074-34682707)x1 ()
🧬 DNM1L: GRCh38/hg38 12p13.33-11.1(chr12:64621-34650483)x3 ()
🧬 DNM1L: GRCh38/hg38 12p13.33-q13.12(chr12:82453-49847230)x3 ()
🧬 DNM1L: NM_012062.5(DNM1L):c.499A>T (p.Arg167Ter) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 220 variantes classificadas pelo ClinVar.

110
110
Patogênica (50.0%)
VUS (50.0%)
VARIANTES MAIS SIGNIFICATIVAS
LOC126806913: NM_130837.3(OPA1):c.1811C>A (p.Ser604Ter) [Likely pathogenic]
OPA1: NM_130837.3(OPA1):c.1036-16_1111del [Likely pathogenic]
OPA1: NM_130837.3(OPA1):c.1241_1245del (p.Leu414fs) [Likely pathogenic]
OPA1: NM_130837.3(OPA1):c.2661+1G>C [Likely pathogenic]
OPA1: NM_130837.3(OPA1):c.3011T>C (p.Leu1004Pro) [Likely pathogenic]

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
2Fase 21
1Fase 11
·Pré-clínico5
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 7 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Neuropatia óptica autossômica dominante

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

3 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

9 ensaios clínicos encontrados, 4 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
152 papers (10 anos)
#1

Disrupted energy metabolism is associated with retinal ganglion cell degeneration in autosomal dominant optic atrophy.

Science advances2026 Feb 20

Autosomal dominant optic atrophy (ADOA) is a hereditary optic neuropathy caused by OPA1 variants, leading to retinal ganglion cell (RGC) degeneration and vision loss. The mechanisms behind RGC vulnerability to mitochondrial dysfunction remain unclear. We developed a patient-specific Opa1V291D/+ knock-in mouse model to investigate mitochondrial dysfunction and retinal metabolism in ADOA. We observed that Opa1V291D/+ mice exhibited anatomical and functional RGC abnormalities recapitulating the ADOA phenotypes. Reduced optic atrophy 1 (OPA1) protein levels were noted in Opa1V291D/+ mice, accompanied by decreased protein stability. Moreover, mitochondrial function was compromised, as indicated by reduced Complex I activity, increased oxidative stress, and diminished adenosine triphosphate production in the retinas of Opa1V291D/+ mice. Spatial metabolomics revealed energy deficits in the inner retina and heightened glycolysis in the outer retina. Immunostaining showed decreased expression of glycolytic proteins in the ganglion cell layer. Single-nucleus RNA sequencing disclosed significant down-regulation of energy-production genes in RGCs, while other retinal cell types remained unaffected. These findings emphasize the specific vulnerability of RGCs to bioenergetic crises, connecting disrupted energy homeostasis to their degeneration. By increasing the nicotinamide adenine dinucleotide (NAD+)/reduced form of NAD+ (NADH) redox ratio through the overexpression of mitochondrial-targeted Lactobacillus brevis NADH oxidase (MitoLbNOX) in RGCs, we demonstrated improved RGC function and survival through enhanced energy metabolism and reduced oxidative stress. These findings confirm that disrupted energy metabolism leads to RGC degeneration and emphasize the enhancement of the NAD+/NADH redox ratio as a promising treatment strategy to protect RGCs from degeneration in ADOA.

#2

A recurrent missense variant in the PPIB gene encoding peptidylprolyl isomerase B underlies adult-onset autosomal dominant optic atrophy.

Genetics in medicine : official journal of the American College of Medical Genetics2026 Jan

Hereditary optic atrophy (OA) represents one of the leading causes of blindness. A relatively large number of genes, many of which are implicated in mitochondrial function, are known to be involved in OA. For many affected individuals, however, a genetic cause still cannot be identified. In a large pedigree and additional families, exome sequencing was used to identify a genetic cause in individuals with so far genetically unresolved OA. Subsequently, mitochondrial function was studied in cultured dermal fibroblasts. Exome sequencing revealed a heterozygous missense variant in PPIB [NM_000942.5:c.538C>T p.(Arg180Trp)], encoding peptidylprolyl isomerase B, which segregated with clinically isolated OA in 19 individuals from 9 families. PPIB-associated OA involves an insidious reduction in visual acuity, central scotoma, and inner retinal layer thinning consistent with other autosomal dominant OAs. Age of symptom onset was mostly in adulthood (median: 36 years), and severity of clinical manifestation was variable. Patient-derived fibroblasts revealed altered mitochondrial morphology, as well as subtle respiratory chain defects. The PPIB variant segregates with OA, which might be caused by compromised mitochondrial function. Although future studies are needed to study the exact pathomechanistic role of PPIB, insights from this work broaden the knowledge of genes implicated in autosomal dominant OA.

#3

A Case Report of Unilateral OPA3-Related Dominant Optic Atrophy.

Case reports in ophthalmology2026

Autosomal dominant optic atrophy (DOA) is an inherited optic neuropathy characterized by progressive bilateral vision loss, cecocentral visual field (VF) defects, and retinal ganglion cell degeneration. Most cases are associated with OPA1 mutations, while OPA3-related DOA is rare and typically involves both eyes. To date, unilateral disease has not been reported. A 33-year-old man presented with progressive, painless vision loss in the left eye. Best corrected visual acuity was 20/20 in the right eye and 20/30 in the left, with a left relative afferent pupillary defect and optic disc pallor. Optical coherence tomography revealed normal retinal nerve fiber layer thickness in the right eye and diffuse thinning in the left; VF testing showed a central scotoma in the left eye. MRI excluded compressive or inflammatory causes. Genetic testing identified a novel heterozygous OPA3 missense variant, c.199G>C, p.Val67Leu, not previously reported in population databases. Four years later, vision in the left eye had declined to 20/100 with persistent unilateral atrophy, while the right eye remained normal. This represents the first documented case of unilateral OPA3-related DOA, challenging the long-held view that DOA is inherently bilateral. Recognition of such atypical presentations may expand the clinical spectrum of OPA3-related disease and inform diagnostic and genetic counseling approaches for patients with unilateral optic neuropathy.

#4

Volumetric brain analysis and associated retinal thinning in autosomal dominant optic atrophy patients.

Neuroimage. Reports2026 Mar

Dominant optic atrophy (DOA) is an inherited mitochondrial disorder characterized by retinal thinning and progressive visual loss. When accompanied by additional neurological or systemic features, such as progressive external ophthalmoplegia, myopathy, or deafness, it is classified as DOA-plus (DOA+). Although central nervous system involvement has been associated with cortical and cerebellar atrophy, specific regional patterns remain unclear. This study aimed to investigate cortical lobe alterations in DOA+ patients and examine the association between retinal thinning and structural changes in the primary visual cortex (V1). Seven DOA+ patients and seven age- and sex-matched healthy controls underwent 3T brain MRI, including 3D T1-weighted imaging, and optical coherence tomography (OCT). Cortical parameters including surface area, gray matter volume, and cortical thickness were quantified using automated whole-brain analysis. Comparisons between DOA+ patients and control groups were performed using independent t-tests, and associations between OCT metrics and V1 cortical measures were assessed with Spearman's rank correlation. DOA+ patients showed a trend toward atrophy in V1 and across all cortical lobes, with statistically significant differences observed only in V1 and occipital lobe (p < 0.001). The occipital lobe demonstrated the greatest reduction in gray matter volume (25.1%, p < 0.001). A positive correlation was observed between average RNFL thickness and average V1 thickness (ρ = 0.90, p = 0.037). DOA+ patients showed significant atrophy in occipital lobe. An association between retinal thinning and average V1 thickness was observed. However, a definite causal relationship cannot be established. Further studies in larger, genetically diverse cohorts are needed to validate these findings.

#5

Advanced therapies for inherited optic neuropathies.

Eye (London, England)2026 Feb

Inherited optic neuropathies (IONs), such as Leber hereditary optic neuropathy (LHON) and autosomal dominant optic atrophy (ADOA), typically lead to irreversible severe vision loss due to mitochondrial dysfunction causing retinal ganglion cell degeneration. Although current treatment options are limited, substantial progress has been made recently in our understanding of the molecular genetic pathways that lead to retinal ganglion cell loss. Clinical trials for LHON have demonstrated the efficacy of idebenone, an oral neuroprotective agent, and gene replacement therapy using allotopic gene expression. Early phase clinical trials are underway for ADOA caused by variants in the nuclear gene OPA1 using innovative techniques to modulate gene expression in a variant-agnostic manner. In this review, we have critically appraised a range of therapeutic strategies, including gene editing and stem cell-based optic nerve regeneration, with a discussion of the barriers to translation. Future studies focussing on understanding genetic heterogeneity, disease variability and optimising patient selection for clinical trials are essential to improve patient management and fast track transformative therapies for IONs.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC138 artigos no totalmostrando 157

2026

Disrupted energy metabolism is associated with retinal ganglion cell degeneration in autosomal dominant optic atrophy.

Science advances
2026

A Case Report of Unilateral OPA3-Related Dominant Optic Atrophy.

Case reports in ophthalmology
2026

Volumetric brain analysis and associated retinal thinning in autosomal dominant optic atrophy patients.

Neuroimage. Reports
2025

Optic Atrophy Predominant WFS1 Disorder-A Case-Control Study.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
2025

Serum neuronal, glial and mitochondrial markers in autosomal dominant optic atrophy and Leber hereditary optic neuropathy.

Brain communications
2025

Clinical and Genetic Findings in an Autosomal Dominant Optic Atrophy-Compatible Phenotype Harboring an OPA1 Variant: A Case Report.

Cureus
2026

Advanced therapies for inherited optic neuropathies.

Eye (London, England)
2025

IT TAKES TWO TO TANGO: potential novel therapies for autosomal dominant optic atrophy.

Frontiers in ophthalmology
2025

Chromatic pupil campimetry as objective diagnostic tool for progressive optic neuropathies.

Documenta ophthalmologica. Advances in ophthalmology
2026

A recurrent missense variant in the PPIB gene encoding peptidylprolyl isomerase B underlies adult-onset autosomal dominant optic atrophy.

Genetics in medicine : official journal of the American College of Medical Genetics
2025

Technological advances in the diagnosis and management of inherited optic neuropathies.

Frontiers in neurology
2025

"Adrift From the World": Exploring the Lived Experiences of Individuals Affected by an Inherited Optic Neuropathy in the United Kingdom-A Qualitative Study.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
2025

Natural History and Biomarker Challenges in Dominant Optic Atrophy: Implications for Therapeutic Studies.

Clinical &amp; experimental ophthalmology
2025

Case of autosomal dominant optic atrophy with relatively good visual function.

BMC ophthalmology
2025

Contrasting pathophysiological mechanisms of OPA1 mutations in autosomal dominant optic atrophy.

Cell death discovery
2025

The crossroads of Leber hereditary optic neuropathy and autosomal dominant optic Atrophy: Clinical profiles of patients with coexisting pathogenic genetic variants.

American journal of ophthalmology case reports
2025

SARM1 loss protects retinal ganglion cells in a mouse model of autosomal dominant optic atrophy.

The Journal of clinical investigation
2025

Longitudinal Visual Biomarkers in Dominant Optic Atrophy: A Systematic Review and Meta-Analysis.

Clinical &amp; experimental ophthalmology
2025

OPA1 mutations in dominant optic atrophy: domain-specific defects in mitochondrial fusion and apoptotic regulation.

Journal of translational medicine
2025

The Balance of MFN2 and OPA1 in Mitochondrial Dynamics, Cellular Homeostasis, and Disease.

Biomolecules
2025

Correlation between quality of vision and clinical and structural parameters in patients with Autosomal Dominant Optic Atrophy.

Eye (London, England)
2025

Targeting OPA1 protein for therapeutic intervention in autosomal dominant optic atrophy: In silico drug discovery.

Journal of molecular graphics &amp; modelling
2025

Frequency and Pattern of Gene Therapy Clinical Trials for Inherited Retinal Diseases.

Advances in experimental medicine and biology
2025

Unraveling the genetic spectrum of inherited deaf-blindness in Portugal.

Orphanet journal of rare diseases
2024

Clinical and Structural Parameters in Autosomal Dominant Optic Atrophy Patients: A Cross-Sectional Study Using Optical Coherence Tomography.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
2024

OPA1 and disease-causing mutants perturb mitochondrial nucleoid distribution.

Cell death &amp; disease
2024

Characteristics of autosomal dominant WFS1-associated optic neuropathy and its comparability to OPA1-associated autosomal dominant optic atrophy.

Scientific reports
2024

Antisense Oligonucleotide STK-002 Increases OPA1 in Retina and Improves Mitochondrial Function in Autosomal Dominant Optic Atrophy Cells.

Nucleic acid therapeutics
2024

Mitochondria in Retinal Ganglion Cells: Unraveling the Metabolic Nexus and Oxidative Stress.

International journal of molecular sciences
2024

Drosophila model to clarify the pathological significance of OPA1 in autosomal dominant optic atrophy.

eLife
2025

Novel heterozygous OPA3 variant in a family with congenital cataracts, sensorineural hearing loss and neuropathy, without optic atrophy and comparison of pathogenic and population variants.

American journal of medical genetics. Part A
2025

Family Planning in Genetic Optic Atrophies in Israel, a Case Series and a Discussion of Ethical Considerations.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
2024

Creation of an Isogenic Human iPSC-Based RGC Model of Dominant Optic Atrophy Harboring the Pathogenic Variant c.1861C>T (p.Gln621Ter) in the OPA1 Gene.

International journal of molecular sciences
2024

Genetic diversity of 1,845 rhesus macaques improves genetic variation interpretation and identifies disease models.

Nature communications
2024

Targeting DRP1 with Mdivi-1 to correct mitochondrial abnormalities in ADOA+ syndrome.

JCI insight
2024

Identifying therapeutic compounds for autosomal dominant optic atrophy (ADOA) through screening in the nematode C. elegans.

Methods in cell biology
2024

Genetic underpinnings explored: OPA1 deletion and complex phenotypes on chromosome 3q29.

BMC medical genomics
2024

Short Wavelength Automated Perimetry, Standard Automated Perimetry, and Optical Coherence Tomography in Dominant Optic Atrophy.

Journal of clinical medicine
2024

[Chinese expert consensus on the clinical diagnosis and treatment of autosomal dominant optic atrophy (2024)].

[Zhonghua yan ke za zhi] Chinese journal of ophthalmology
2024

OPA1 mutation affects autophagy and triggers senescence in autosomal dominant optic atrophy plus fibroblasts.

Human molecular genetics
2024

Human retinal organoids with an OPA1 mutation are defective in retinal ganglion cell differentiation and function.

Stem cell reports
2023

Multi-omics analysis of the oncogenic role of optic atrophy 1 in human cancer.

Aging
2023

Pyrroloquinoline quinone drives ATP synthesis in vitro and in vivo and provides retinal ganglion cell neuroprotection.

Acta neuropathologica communications
2023

Visual Function and Inner Retinal Structure in Relation to Birth Factors in Autosomal Dominant Optic Atrophy.

Investigative ophthalmology &amp; visual science
2023

Ginsenoside Rg1 protects cardiac mitochondrial function via targeting GSTP1 to block S-glutathionylation of optic atrophy 1.

Free radical biology &amp; medicine
2023

Caenorhabditis elegans as a Model System to Study Human Neurodegenerative Disorders.

Biomolecules
2023

Identification of AFG3L2 dominant optic atrophy following reanalysis of clinical exome sequencing.

American journal of ophthalmology case reports
2023

OPA1 disease-causing mutants have domain-specific effects on mitochondrial ultrastructure and fusion.

Proceedings of the National Academy of Sciences of the United States of America
2023

Mitochondrial optic neuropathies.

Handbook of clinical neurology
2023

Choroidal vascularity index in hereditary optic neuropathies.

Eye (London, England)
2023

The effects of nuclear DNA mutations on mitochondrial function.

Journal of the American Association of Nurse Practitioners
2023

The effect of serifs and stroke contrast on low vision reading.

Acta psychologica
2023

Mechanistic study of optic atrophy 1 in ischemia-reperfusion disease.

Journal of molecular medicine (Berlin, Germany)
2023

Expanding SPG7 dominant optic atrophy phenotype: Infantile nystagmus and optic atrophy without spastic paraplegia.

American journal of medical genetics. Part A
2022

Metabolic reprogramming in the OPA1-deficient cells.

Cellular and molecular life sciences : CMLS
2022

Generation of induced pluripotent stem cells from a patient with hearing loss carrying OPA1 c.1468T>C (p.Cys490Arg) variant.

Stem cell research
2023

The importance of genome sequencing: unraveling SSBP1 variant missed by exome sequencing.

Ophthalmic genetics
2022

Autosomal dominant optic atrophy caused by six novel pathogenic OPA1 variants and genotype-phenotype correlation analysis.

BMC ophthalmology
2022

Modelling autosomal dominant optic atrophy associated with OPA1 variants in iPSC-derived retinal ganglion cells.

Human molecular genetics
2022

Characterisation of a novel OPA1 splice variant resulting in cryptic splice site activation and mitochondrial dysfunction.

European journal of human genetics : EJHG
2022

Photoreceptor Manifestations of Primary Mitochondrial Optic Nerve Disorders.

Investigative ophthalmology &amp; visual science
2022

Prevalence of Macular Microcystoid Lacunae in Autosomal Dominant Optic Atrophy Assessed With Adaptive Optics.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
2023

Comparison of the clinical and genetic features of autosomal dominant optic atrophy and normal tension glaucoma in young Chinese adults.

Eye (London, England)
2022

Vision-related quality of life and visual ability in patients with autosomal dominant optic atrophy.

Acta ophthalmologica
2021

OPA1 Modulates Mitochondrial Ca2+ Uptake Through ER-Mitochondria Coupling.

Frontiers in cell and developmental biology
2021

Mitochondrial Retinopathies.

International journal of molecular sciences
2022

Omega-3 fatty acids promote neuroprotection, decreased apoptosis and reduced glial cell activation in the retina of a mouse model of OPA1-related autosomal dominant optic atrophy.

Experimental eye research
2021

Autosomal dominant optic atrophy: A novel treatment for OPA1 splice defects using U1 snRNA adaption.

Molecular therapy. Nucleic acids
2021

Oxidative Stress in Optic Neuropathies.

Antioxidants (Basel, Switzerland)
2021

[New possibilities in diagnosis of hereditary optic neuropathies].

Vestnik oftalmologii
2022

Induced Pluripotent Stem Cells for Inherited Optic Neuropathies-Disease Modeling and Therapeutic Development.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
2021

CRISPR-Cas9 correction of OPA1 c.1334G>A: p.R445H restores mitochondrial homeostasis in dominant optic atrophy patient-derived iPSCs.

Molecular therapy. Nucleic acids
2021

Genetic Spectrum and Characteristics of Hereditary Optic Neuropathy in Taiwan.

Genes
2022

Mutations at a split codon in the GTPase-encoding domain of OPA1 cause dominant optic atrophy through different molecular mechanisms.

Human molecular genetics
2022

Delayed diagnosis of autosomal dominant optic atrophy until seventh decade of life.

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
2021

Red Light Irradiation In Vivo Upregulates DJ-1 in the Retinal Ganglion Cell Layer and Protects against Axotomy-Related Dendritic Pruning.

International journal of molecular sciences
2022

Associations between OPA1, MFN1, and MFN2 polymorphisms and primary open angle glaucoma in Polish participants of European ancestry.

Ophthalmic genetics
2022

Sustained intracellular calcium rise mediates neuronal mitophagy in models of autosomal dominant optic atrophy.

Cell death and differentiation
2021

Colour-centred Release Hallucinations in a Patient with Early Parkinson's Disease and Unrecognised Autosomal Dominant Optic Atrophy.

Neuro-ophthalmology (Aeolus Press)
2021

New avenues for therapy in mitochondrial optic neuropathies.

Therapeutic advances in rare disease
2022

Optical coherence tomography angiography in the multimodal assessment of the retinal posterior pole in autosomal dominant optic atrophy.

Acta ophthalmologica
2021

Mutation spectrum of the OPA1 gene in a large cohort of patients with suspected dominant optic atrophy: Identification and classification of 48 novel variants.

PloS one
2021

High-throughput screening identifies suppressors of mitochondrial fragmentation in OPA1 fibroblasts.

EMBO molecular medicine
2022

WFS1 protein expression correlates with clinical progression of optic atrophy in patients with Wolfram syndrome.

Journal of medical genetics
2021

Neuroinflammatory Mechanisms of Mitochondrial Dysfunction and Neurodegeneration in Glaucoma.

Journal of ophthalmology
2021

A Perspective on Accelerated Aging Caused by the Genetic Deficiency of the Metabolic Protein, OPA1.

Frontiers in neurology
2021

[Clinical characteristics and research progress on the treatment of mitochondrial optic neuropathy].

[Zhonghua yan ke za zhi] Chinese journal of ophthalmology
2021

Pathogenicity evaluation and the genotype-phenotype analysis of OPA1 variants.

Molecular genetics and genomics : MGG
2021

Generation of an induced pluripotent stem cell line BIOi002-A from a patient with autosomal dominant optic atrophy.

Stem cell research
2021

OPA1 haploinsufficiency due to a novel splicing variant resulting in mitochondrial dysfunction without mitochondrial DNA depletion.

Ophthalmic genetics
2020

Genomics combined with a protein informatics platform to assess a novel pathogenic variant c.1024 A>G (p.K342E) in OPA1 in a patient with autosomal dominant optic atrophy.

Ophthalmic genetics
2020

Mutation Screening of mtDNA Combined Targeted Exon Sequencing in a Cohort With Suspected Hereditary Optic Neuropathy.

Translational vision science &amp; technology
2020

Inhibition of autophagy curtails visual loss in a model of autosomal dominant optic atrophy.

Nature communications
2020

A novel AFG3L2 mutation close to AAA domain leads to aberrant OMA1 and OPA1 processing in a family with optic atrophy.

Acta neuropathologica communications
2022

BILATERAL EPIRETINAL MEMBRANE FORMATION AFTER INTRAVITREAL INJECTIONS OF AUTOLOGOUS MESENCHYMAL STEM CELLS.

Retinal cases &amp; brief reports
2020

Opa1 Deficiency Leads to Diminished Mitochondrial Bioenergetics With Compensatory Increased Mitochondrial Motility.

Investigative ophthalmology &amp; visual science
2020

Comparison of Lamina Cribrosa Morphology in Normal Tension Glaucoma and Autosomal-Dominant Optic Atrophy.

Investigative ophthalmology &amp; visual science
2020

Harnessing the protective role of OPA1 in diabetic cardiomyopathy.

Acta physiologica (Oxford, England)
2020

Heterozygous type 1 Autosomal Dominant Optic Atrophy (ADOA) with OPA1 c.1936-2A>G genetic variant.

Journal francais d'ophtalmologie
2019

Mitochondrial Gymnastics in Retinal Cells: A Resilience Mechanism Against Oxidative Stress and Neurodegeneration.

Advances in experimental medicine and biology
2019

Autosomal dominant optic atrophy with OPA1 gene mutations accompanied by auditory neuropathy and other systemic complications in a Japanese cohort.

Molecular vision
2020

Thickness mapping of individual retinal layers and sectors by Spectralis Spectral Domain-optical Coherence Tomography in Autosomal Dominant Optic Atrophy.

Acta ophthalmologica
2019

SSBP1 mutations in dominant optic atrophy with variable retinal degeneration.

Annals of neurology
2019

Structure and assembly of the mitochondrial membrane remodelling GTPase Mgm1.

Nature
2019

Autosomal dominant optic atrophy plus due to the novel OPA1 variant c.1463G>C.

Metabolic brain disease
2019

Autosomal dominant optic atrophy and cataract "plus" phenotype including axonal neuropathy.

Neurology. Genetics
2019

Metabolic stroke in a patient with bi-allelic OPA1 mutations.

Metabolic brain disease
2019

Analysis of Inherited Optic Neuropathies.

Klinische Monatsblatter fur Augenheilkunde
2019

Peripapillary and macular morpho-vascular changes in patients with genetic or clinical diagnosis of autosomal dominant optic atrophy: a case-control study.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
2018

[Genetic Causes and Genetic Diagnostic Testing of Inherited Optic Atrophies].

Klinische Monatsblatter fur Augenheilkunde
2018

Validating the RedMIT/GFP-LC3 Mouse Model by Studying Mitophagy in Autosomal Dominant Optic Atrophy Due to the OPA1Q285STOP Mutation.

Frontiers in cell and developmental biology
2018

Novel truncating mutation in CACNA1F in a young male patient diagnosed with optic atrophy.

Ophthalmic genetics
2019

Genetic analysis in a cohort of patients with hereditary optic neuropathies in Southwest of China.

Mitochondrion
2019

Meta-analysis of genotype-phenotype analysis of OPA1 mutations in autosomal dominant optic atrophy.

Mitochondrion
2018

Clinical and genetic features of eight Chinese autosomal-dominant optic atrophy pedigrees with six novel OPA1 pathogenic variants.

Ophthalmic genetics
2018

Dietary fat is a key determinant in balancing mitochondrial dynamics in heart failure: a novel mechanism underlying the obesity paradox.

Cardiovascular research
2018

The expanding neurological phenotype of DNM1L-related disorders.

Brain : a journal of neurology
2018

[Hereditary Optic Neuropathies].

Klinische Monatsblatter fur Augenheilkunde
2017

Non-syndromic isolated dominant optic atrophy caused by the p.R468C mutation in the AFG3 like matrix AAA peptidase subunit 2 gene.

Biomedical reports
2017

Genotype-phenotype and OCT correlations in Autosomal Dominant Optic Atrophy related to OPA1 gene mutations: Report of 13 Italian families.

Journal of the neurological sciences
2018

Thickness mapping of individual retinal layers and sectors by Spectralis SD-OCT in Autosomal Dominant Optic Atrophy.

Acta ophthalmologica
2018

Mitochondrial disorders of the retinal ganglion cells and the optic nerve.

Mitochondrion
2017

Rescue of cell death and inflammation of a mouse model of complex 1-mediated vision loss by repurposed drug molecules.

Human molecular genetics
2017

Nonsyndromic Parkinson disease in a family with autosomal dominant optic atrophy due to OPA1 mutations.

Neurology. Genetics
2017

Processing of OPA1 with a novel N-terminal mutation in patients with autosomal dominant optic atrophy: Escape from nonsense-mediated decay.

PloS one
2017

A novel ADOA-associated OPA1 mutation alters the mitochondrial function, membrane potential, ROS production and apoptosis.

Scientific reports
2017

Pupillometric evaluation of the melanopsin containing retinal ganglion cells in mitochondrial and non-mitochondrial optic neuropathies.

Mitochondrion
2017

Not only dominant, not only optic atrophy: expanding the clinical spectrum associated with OPA1 mutations.

Orphanet journal of rare diseases
2017

Assessment of the retinal posterior pole in dominant optic atrophy by spectral-domain optical coherence tomography and microperimetry.

PloS one
2017

Characterization of two novel intronic OPA1 mutations resulting in aberrant pre-mRNA splicing.

BMC medical genetics
2017

Optic nerve head microcirculation in autosomal dominant optic atrophy and normal-tension glaucoma.

Acta ophthalmologica
2017

The Pattern of Retinal Ganglion Cell Loss in OPA1-Related Autosomal Dominant Optic Atrophy Inferred From Temporal, Spatial, and Chromatic Sensitivity Losses.

Investigative ophthalmology &amp; visual science
2017

[Differential diagnosis of juvenile normal pressure glaucoma].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
2017

Multiethnic involvement in autosomal-dominant optic atrophy in Singapore.

Eye (London, England)
2016

The reduction of temporal optic nerve head microcirculation in autosomal dominant optic atrophy.

Acta ophthalmologica
2016

A neurodegenerative perspective on mitochondrial optic neuropathies.

Acta neuropathologica
2016

Mitochondrial dysfunction in an Opa1(Q285STOP) mouse model of dominant optic atrophy results from Opa1 haploinsufficiency.

Cell death &amp; disease
2016

Emerging Mitochondrial Therapeutic Targets in Optic Neuropathies.

Pharmacology &amp; therapeutics
2016

Exome sequencing identified a novel de novo OPA1 mutation in a consanguineous family presenting with optic atrophy.

Genetics research
2016

Increased steroidogenesis promotes early-onset and severe vision loss in females with OPA1 dominant optic atrophy.

Human molecular genetics
2016

Recessive optic atrophy, sensorimotor neuropathy and cataract associated with novel compound heterozygous mutations in OPA1.

Molecular medicine reports
2016

Molecular Impairment Mechanisms of Novel OPA1 Mutations Predicted by Molecular Modeling in Patients With Autosomal Dominant Optic Atrophy and Auditory Neuropathy Spectrum Disorder.

Otology &amp; neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
2017

The OPA1 Gene Mutations Are Frequent in Han Chinese Patients with Suspected Optic Neuropathy.

Molecular neurobiology
2016

Modeling autosomal dominant optic atrophy using induced pluripotent stem cells and identifying potential therapeutic targets.

Stem cell research &amp; therapy
2015

Electrophysiological ON and OFF Responses in Autosomal Dominant Optic Atrophy.

Investigative ophthalmology &amp; visual science
2016

A novel 3q29 deletion associated with autism, intellectual disability, psychiatric disorders, and obesity.

American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics
2015

Therapeutic Approaches to Inherited Optic Neuropathies.

Seminars in neurology
2015

Identification of copy number variation in the gene for autosomal dominant optic atrophy, OPA1, in a Chinese pedigree.

Genetics and molecular research : GMR
2015

Genotype-phenotype heterogeneity of ganglion cell and inner plexiform layer deficit in autosomal-dominant optic atrophy.

Acta ophthalmologica
2015

Influence of Opa1 Mutation on Survival and Function of Retinal Ganglion Cells.

Investigative ophthalmology &amp; visual science
2015

A novel OPA1 mutation causing variable age of onset autosomal dominant optic atrophy plus in an Australian family.

Journal of neurology
2015

Implications of mitochondrial dynamics on neurodegeneration and on hypothalamic dysfunction.

Frontiers in aging neuroscience
2015

Analysis of opa1 isoforms expression and apoptosis regulation in autosomal dominant optic atrophy (ADOA) patients with mutations in the opa1 gene.

Journal of the neurological sciences
2015

Diffusion Tensor Imaging Mapping of Brain White Matter Pathology in Mitochondrial Optic Neuropathies.

AJNR. American journal of neuroradiology
2015

Changes in Mitochondrial Morphology and Bioenergetics in Human Lymphoblastoid Cells With Four Novel OPA1 Mutations.

Investigative ophthalmology &amp; visual science
2015

Dissociation of Pupillary Post-Illumination Responses from Visual Function in Confirmed OPA1 c.983A > G and c.2708_2711delTTAG Autosomal Dominant Optic Atrophy.

Frontiers in neurology
2015

Neuroradiological findings expand the phenotype of OPA1-related mitochondrial dysfunction.

Journal of the neurological sciences

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Neuropatia óptica autossômica dominante.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Neuropatia óptica autossômica dominante

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Disrupted energy metabolism is associated with retinal ganglion cell degeneration in autosomal dominant optic atrophy.
    Science advances· 2026· PMID 41706861mais citado
  2. A recurrent missense variant in the PPIB gene encoding peptidylprolyl isomerase B underlies adult-onset autosomal dominant optic atrophy.
    Genetics in medicine : official journal of the American College of Medical Genetics· 2026· PMID 41045073mais citado
  3. A Case Report of Unilateral OPA3-Related Dominant Optic Atrophy.
    Case reports in ophthalmology· 2026· PMID 41567320mais citado
  4. Volumetric brain analysis and associated retinal thinning in autosomal dominant optic atrophy patients.
    Neuroimage. Reports· 2026· PMID 41561141mais citado
  5. Advanced therapies for inherited optic neuropathies.
    Eye (London, England)· 2026· PMID 41318849mais citado
  6. Rhesus macaques with an OPA1 mutation demonstrate features of autosomal dominant optic atrophy.
    Proc Natl Acad Sci U S A· 2026· PMID 41984835recente
  7. Impact of Inner Retinal Layer Thinning on Visual Function in OPA1 Autosomal Dominant Optic Atrophy and Associations With Age and Genetic Variant Class.
    Invest Ophthalmol Vis Sci· 2026· PMID 41944540recente
  8. Frequency and Hearing Loss Phenotypes of OPA1 Variants in a Cohort of 18,475 Patients with Hearing Impairment.
    Genes (Basel)· 2026· PMID 41898875recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:98672(Orphanet)
  2. MONDO:0020250(MONDO)
  3. GARD:11972(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q29982071(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Neuropatia óptica autossômica dominante
Compêndio · Raras BR

Neuropatia óptica autossômica dominante

ORPHA:98672 · MONDO:0020250
Prevalência
1-9 / 100 000
Herança
Autosomal dominant
Ensaios
4 ativos
Início
Childhood
Prevalência
10.0 (Denmark)
MedGen
UMLS
C0338508
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades